Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P890055/S092

lntera 3000 Hepatic Artery Infusion Pump

Intera Oncology · Decision date Feb 26, 2026

FDA DECISIONP890055/S092

What did the FDA approve?

FDA records P890055/S092 as a supplement to PMA P890055, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 26, 2026.

FDA approval order statement

Approval for updates to the labeling and instructions for use.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
General Hospital
Decision date
Feb 26, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P890055/S092
Regulatory pathway
PMA supplement
Product code
LKK
Decision code
APPR
Decision date
Feb 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pump, infusion, implanted, programmable.

Product code
LKK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P890055/S092 received

    Application receipt date recorded by FDA.

  2. P890055/S092 · FDA decision

    Real-Time Process

  3. P890055/S093 · Related supplement

    MEDSTREAM PROGRAMMABLE INFUSION PUMP SYSTEM

Timeline entries are records held by MedtechLedger for P890055. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P890055

Product / regulatory recordCompanyPathwayDecision dateSource
Intera OncologyPMA supplementMar 16, 2026FDA

Explore the linked device profile

Other records with product code LKK

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Intera Oncology

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
180 Wells Ave., Suite 300a, Newton, MA, 02459

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records